ECSP19055169A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents
Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)Info
- Publication number
- ECSP19055169A ECSP19055169A ECSENADI201955169A ECDI201955169A ECSP19055169A EC SP19055169 A ECSP19055169 A EC SP19055169A EC SENADI201955169 A ECSENADI201955169 A EC SENADI201955169A EC DI201955169 A ECDI201955169 A EC DI201955169A EC SP19055169 A ECSP19055169 A EC SP19055169A
- Authority
- EC
- Ecuador
- Prior art keywords
- ahr
- aryl hydrocarbon
- hydrocarbon receptor
- modulating compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000158 | 2017-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19055169A true ECSP19055169A (es) | 2019-08-30 |
Family
ID=57960223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201955169A ECSP19055169A (es) | 2017-02-01 | 2019-07-31 | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10981908B2 (es) |
| EP (1) | EP3577112B1 (es) |
| JP (1) | JP6849823B2 (es) |
| KR (1) | KR102320516B1 (es) |
| CN (1) | CN110248940B (es) |
| AR (1) | AR110789A1 (es) |
| AU (1) | AU2018216957B2 (es) |
| BR (1) | BR112019015716A2 (es) |
| CA (1) | CA3050827C (es) |
| CL (1) | CL2019002108A1 (es) |
| CO (1) | CO2019007881A2 (es) |
| CR (1) | CR20190392A (es) |
| CU (1) | CU20190069A7 (es) |
| EA (1) | EA038318B1 (es) |
| EC (1) | ECSP19055169A (es) |
| ES (1) | ES2858329T3 (es) |
| IL (1) | IL268080B (es) |
| MX (1) | MX2019008994A (es) |
| MY (1) | MY196831A (es) |
| NI (1) | NI201900076A (es) |
| PE (1) | PE20191478A1 (es) |
| PH (1) | PH12019550135A1 (es) |
| SG (1) | SG11201906958TA (es) |
| TW (1) | TWI752155B (es) |
| UA (1) | UA122745C2 (es) |
| UY (1) | UY37589A (es) |
| WO (1) | WO2018141857A1 (es) |
| ZA (1) | ZA201904771B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ＡｈＲモジュレータ |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| SG11202105213XA (en) * | 2018-11-30 | 2021-06-29 | Celularity Inc | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds |
| WO2021148628A1 (en) * | 2020-01-23 | 2021-07-29 | Phenex Pharmaceuticals Ag | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| WO2021173082A1 (en) | 2020-02-26 | 2021-09-02 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| US20230234967A1 (en) * | 2020-05-28 | 2023-07-27 | Senda Biosciences, Inc. | Fused Azole Heterocycles as AHR Antagonists |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8225991A (en) | 1990-07-31 | 1992-03-02 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
| WO1998022457A1 (en) * | 1996-11-19 | 1998-05-28 | Amgen Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| RU2417226C2 (ru) | 2005-11-18 | 2011-04-27 | Ф.Хоффманн-Ля Рош Аг | Производные азаиндол-2-карбоксамида |
| US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| EP3689347A1 (en) * | 2009-11-02 | 2020-08-05 | Ariagen, Inc. | Ite for cancer intervention and eradication |
| ES2445917T3 (es) | 2010-02-03 | 2014-03-06 | Takeda Pharmaceutical Company Limited | Inhibidores de quinasa 1 reguladora de la señal de apoptosis |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| EA035288B1 (ru) | 2010-07-27 | 2020-05-25 | Трастис Оф Бостон Юниверсити | МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| RU2015115677A (ru) | 2012-10-17 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | Производные 6-аминоиндола в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp) |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-26 TW TW107102803A patent/TWI752155B/zh active
- 2018-01-31 AR ARP180100227A patent/AR110789A1/es unknown
- 2018-01-31 UY UY0001037589A patent/UY37589A/es not_active Application Discontinuation
- 2018-02-01 PE PE2019001482A patent/PE20191478A1/es unknown
- 2018-02-01 US US16/479,130 patent/US10981908B2/en active Active
- 2018-02-01 MX MX2019008994A patent/MX2019008994A/es unknown
- 2018-02-01 WO PCT/EP2018/052542 patent/WO2018141857A1/en unknown
- 2018-02-01 EA EA201991599A patent/EA038318B1/ru unknown
- 2018-02-01 CU CU2019000069A patent/CU20190069A7/es unknown
- 2018-02-01 CA CA3050827A patent/CA3050827C/en active Active
- 2018-02-01 CN CN201880009354.9A patent/CN110248940B/zh active Active
- 2018-02-01 BR BR112019015716-6A patent/BR112019015716A2/pt not_active IP Right Cessation
- 2018-02-01 CR CR20190392A patent/CR20190392A/es unknown
- 2018-02-01 EP EP18701774.4A patent/EP3577112B1/en active Active
- 2018-02-01 JP JP2019561370A patent/JP6849823B2/ja active Active
- 2018-02-01 KR KR1020197023990A patent/KR102320516B1/ko active IP Right Grant
- 2018-02-01 UA UAA201908353A patent/UA122745C2/uk unknown
- 2018-02-01 MY MYPI2019004031A patent/MY196831A/en unknown
- 2018-02-01 AU AU2018216957A patent/AU2018216957B2/en not_active Ceased
- 2018-02-01 SG SG11201906958TA patent/SG11201906958TA/en unknown
- 2018-02-01 ES ES18701774T patent/ES2858329T3/es active Active
-
2019
- 2019-07-15 IL IL268080A patent/IL268080B/en unknown
- 2019-07-15 NI NI201900076A patent/NI201900076A/es unknown
- 2019-07-19 ZA ZA2019/04771A patent/ZA201904771B/en unknown
- 2019-07-23 CO CONC2019/0007881A patent/CO2019007881A2/es unknown
- 2019-07-24 PH PH12019550135A patent/PH12019550135A1/en unknown
- 2019-07-29 CL CL2019002108A patent/CL2019002108A1/es unknown
- 2019-07-31 EC ECSENADI201955169A patent/ECSP19055169A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP19055169A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP19055179A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
| GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| UY36445A (es) | Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi) | |
| ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
| UY36452A (es) | Novedosos compuestos moduladores de fxr (nr1h4) | |
| DOP2016000125A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| CO7160047A2 (es) | Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr) | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY35993A (es) | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina | |
| UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
| GT201600255A (es) | Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas |